HIV Drug Therapy Latest News2003-12-13T18:30:02Zhivdrugtherapy.orgurn:uuid:60a76c80-d399-11d9-b93C-0003939e0af6Drug Interactions - Vinblastine and boosted PIs.Drug Interactions - Rifampicin and lopinavir in children.Review - Raltegravir.Drug Interactions - Buprenorphine/naloxone and once daily lopinavir/ritonavir.Correspondence - Switching from efavirenz to nevirapine.Review - Managing drug interactions.Meeting Report - 18th World AIDS Conference, Vienna.Pharmacokinetics – Once daily darunavir/ritonavir and efavirenzReview – Effect of herbals on drug absorptionCase report – lack of PK interaction between bosentan and nevirapineWebcast – PK and Drug Interactions.Review - MaravirocPharmacokinetics - Darunavir/ritonavir and hepatic impairment.Review - QT interval prolongationDrug Interactions - Use of the website to determine prevalence of drug interaction in the Swiss HIV Cohort.Herbals - Effect of danshen on CYP3A4Drug Interactions - Prevalence of clinically significant interactions in a clinical cohort.Drug Interactions - Lersivirine and antacids.Review - Intracellular pharmacokinetics of antiretrovirals.Meeting Report - 11th PK Workshop, Sorrento, April 2010.Case Reports - IV docetaxel and ritonavir.Review - Warfarin and antiretrovirals.Review - Management of HIV/TB co-infection.Drug Interactions - Ritonavir and quinine.Drug Interactions - Tenofovir and boosted or unboosted fosamprenavir.Drug interactions - Combined administration of potent CYP3A inducers and inhibitors.Meeting Report - Drug interactions at 17th CROI.Drug Interaction - Elvitegravir/ritonavir and maraviroc.Drug Interactions - Nevirapine and atazanavirReview - Treating HIV/AIDS and substance abuse.Review - HIV internet resources.Review - Antiretrovirals and the kidney.Drug Interactions - Maraviroc and raltegravir.Drug Interactions - GS-9350 and midazolamReview - Comment on review by Brown et al.Review - Vicriviroc.Case Reports - Quetiapine and atazanavir/ritonavir.Drug Interactions - Tipranavir/ritonavir and efavirenz.Drug Interactions - Rifabutin and lopinavir/ritonavir.Drug Interactions - Tipranavir/ritonavir and statins.Meeting Report - 12th EACS, Cologne, November 2009.Review - Pharmacokinetics and interactions of new antiretrovirals.Drug Interactions - Raltegravir/etravirine clinical trial data.Webcast - HIV and AgeingDrug Interactions - Lopinavir and gemfibrozil.Drug Interactions - Etravirine after stopping efavirenz.Drug Interactions - Efavirenz and rifampicin in South Africans.Drug Interactions - Raltegravir and lamotrigine.Drug interactions - Ritonavir and albendazole or mebendazole.Meeting Report - 49th ICAAC, San Francisco, September 2009.Herbals - Updated review on interactions.Review - EtravirineDrug Interactions - Interactions with immunosuppressants.Drug Interactions - Raltegravir and darunavir/ritonavir or rifampicin.Herbals - Korean Red GinsengCase Report - Ritonavir and triamcinolone.Drug Interaction - Nevirapine and darunavir/ritonavir.Drug Interactions - Docetaxel and ritonavir (100 mg).Drug Interactions - Posaconazole with ATV, ATV/r or EFV.Drug Interactions - Saquinavir concentrations with 50 mg ritonavir in Thai patients.Webcasts - PK Presentations from IAS 2009.Drug Interaction - Darunavir and nevirapine.Meeting Report - 5th IAS Conference, Cape Town, July 2009.Drug Interactions - Rifampicin and NNRTIsDrug Interaction - Artemether/lumefantrine and lopinavir.Drug Interaction - More on raltegravir and etravirine.Drug Interaction - Raltegravir and immunosuppressants.Review - Interactions with new and investigational antiretrovirals.Drug Interactions - Ginkgo and efavirenz.Case Reports - Development of resistant TB with rifabutin and boosted protease inhibitors.Case Reports - Etravirine-Raltegravir interaction.Drug Interactions - Correspondence on interactions with rifampicin.Review - DarunavirCase Reports - Difficult Pharmacology Case Presentations from BHIVA meetingDrug Interaction Alert - Swine FluReview - EtravirineMeeting Report – 10th Pharmacology Workshop, Amsterdam, April 2009.Case Report - Darunavir/ritonavir and tacrolimus interaction.Drug Interactions - Efavirenz and rifampicin in children.Review - RaltegravirWebcasts – Presentations on drug interactionsDrug Interactions - Rifampicin and atazanavir/ritonavir.Drug Interactions - Raltegravir and omeprazole.Drug Interactions - Saquinavir/ritonavir and ketoconazole.Drug Interactions - Dose response of ritonavir on elvitegravir exposure.Drug Interactions - Tipranavir/ritonavir and clarithromycin, fluconazole or rifabutin.Drug Interactions - Article and presentation on interactions with newer antiretroviralsMeeting Report - 16th CROI, Montreal, February 2009.Case Report - Use of TDM to manage the efavirenz-rifampicin interaction.Case report - Protease inhibitors and Cat's claw.Review - Interactions with statins and ART.Review - Drug interactions with new antiretrovirals.Drug Interactions - Raltegravir and etravirine.Review - Interactions with antifungalsDrug Interactions - Lack of interaction between elvitegravir/ritonavir and etravirine.Drug Interactions - Raltegravir and ritonavir or efavirenzDrug Interactions - Hyperbilirubinaemia with atazanavir and ribavirinReview - Interactions with integrase inhibitors.Meeting Report - HIV9, Glasgow, November 2008.Drug Interactions - Elvitegravir with tipranavir/ritonavir or darunavir/ritonavir.Drug Interactions - Effect on tacrolimus when switching from nelfinavir to fosamprenavir.Drug Interactions - Efavirenz and ItraconazoleMeeting Report - 48th ICAAC, Washington, October 2008Drug Interactions - Key papers on methadone and ritonavir.Drug Interactions - Atazanavir/ritonavir with minocyline and valproic acidDrug Interactions - Predicting interactions with maravirocHigh genital HIV levels may persist in women who appear to achieve viral suppression with use of ARTHIV-positive women whose
plasma HIV RNA viral loads drop to undetectable levels following initiation of
ART still may have intermittent surges in the amount of virus in their genital
secretions, according to a US
study.
The study analysed changes
over the course of one year in the plasma and genital tract HIV levels of US
women takinghttp://www.aidsmap.com/page/1509765/Recurrent pneumonia increases lung cancer risk for patients with AIDSRecurrent bacterial pneumonia is associated
with an increased risk of lung cancer in patients with AIDS, US investigators
report in the online edition of the Journal
of Acquired Immune Deficiency Syndromes. The association between pneumonia
and lung cancer was especially strong amongst patients below 50.
The investigators believe that recurrent
pneumonia could be causing inflammation,http://www.aidsmap.com/page/1509759/Kenyan study shows people with HIV can provide safe, effective community management of ARTCommunity-based
care delivered to adults living with HIV by people living with HIV using mobile
technologies provided care as safe and effective as clinic-based care,
researchers report in the advance online edition of the Journal of Acquired Immune Deficiency Syndromes.
This prospective
community randomised clinical pilot study was conducted in villages surrounding
a rural clinichttp://www.aidsmap.com/page/1509006/Imiquimod a good treatment for pre-cancerous anal lesions in men with HIVHIV treatment centres should screen and
treat pre-cancerous anal lesions, UK investigators argue in the
online edition of AIDS. They were
prompted to make this suggestion by research showing that treatment with
imiquimod cream resolved or downgraded high-grade pre-cancerous anal lesions in
61% of HIV-positive gay men.
Although the investigators do not claim
that imiquimod willhttp://www.aidsmap.com/page/1507497/People with HIV with higher CD4 counts should not miss seasonal flu jabsHIV-positive patients with a CD4 cell count
below 350 cells/mm3 have an impaired immune response to the seasonal
influenza (flu) vaccine, Swiss investigators report in the September 10th
edition of AIDS. They recommend that all HIV-positive patients
should have an annual influenza vaccine to help them to establish flu-specific
memory immune cells, the formation ofhttp://www.aidsmap.com/page/1507509/Nevirapine toxicity in women predicted by liver function, not CD4 count, developing country study reportsAbnormal liver function tests at baseline, not CD4 cell
counts over 250 cells/mm³,
were predictors for severe liver damage and associated rash researchers among
women in Zambia, Thailand and Kenya on a nevirapine-based
antiretroviral regimen reported in a multi-country prospective cohort study published
in the advance online edition of HIV
Medicine.
Close to 70 percent of thehttp://www.aidsmap.com/page/1507585/Vitamin A supplements linked to high HIV levels in breast milkResearch in Tanzania shows
that women with HIV who took vitamin A and beta-carotene (VA/BC) supplements
had more HIV in their breast milk than those who did not, while women who took
multivitamins were more likely to develop mastitis. Both are major risk factors
for HIV transmission during breastfeeding
The discovery of
an association between vitaminhttp://www.aidsmap.com/page/1507546/Many HIV-positive gay men have post-traumatic stress disorderA third of HIV-positive gay men have
post-traumatic stress disorder, UK investigators report in AIDS Patient Care and STDs. Events including starting treatment,
HIV-related illness, and witnessing an HIV-related death were all linked to the
development of symptoms associated with post-traumatic stress disorder. Emotional
responses to such events - rather than actual physical threathttp://www.aidsmap.com/page/1506783/Low CD4 cell count associated with poor response to swine flu vaccine for those with HIVMany HIV-positive patients do not develop
protective antibody levels after receiving the standard dose of the swine flu
vaccine, a study published in the September 10th edition of AIDS shows. A low current CD4 cell count
was the only factor associated with a poor response to the vaccine.
“The implications of this researchhttp://www.aidsmap.com/page/1506780/Haiti study shows lab tests sometimes cost-effective for HIV, even in poorest countriesOnly routine laboratory monitoring for asymptomatic anaemia was
clinically beneficial and cost-effective when compared to symptom-driven
testing in a study of HIV-positive patients in Haiti.
The retrospective study of a cohort of 1800 adult patients
at the Haitian Study Group for Kaposi’s sarcoma and Opportunistic Infections
(GHESKIO) in Haiti
on antiretroviral treatment from 2003 to 2006http://www.aidsmap.com/page/1506921/